Opioid-induced "nodding" is commonly misinterpreted as benign sleep but represents a high-risk state of fluctuating consciousness caused by drug-induced respiratory depression. This condition may lead to progressive hypoxia and hypercapnia without normal protective arousal. In the fentanyl era, nodding may reflect a subclinical overdose, with a dangerously narrow transition between sedation and fatal respiratory failure, particularly when opioids are combined with alcohol, benzodiazepines, or other sedative agents. We utilized PUBMED to adopt various works linked to this important topic. Accumulating clinical and neuroimaging evidence suggests that repeated non-fatal overdose events and nodding episodes may contribute to cumulative hypoxic-ischemic brain injury, hippocampal volume loss, and persistent cognitive impairment. Current surveillance systems largely emphasize mortality, thereby underestimating the neurological burden among survivors. Public health and clinical frameworks should redefine nodding as a sentinel respiratory-compromise state and prioritize early intervention, expanded reporting, and improved harm-reduction strategies.
We examine the relationship between substance use disorder (SUD) and schizophrenia, emphasizing the role of dopaminergic neurotransmission and genetic predispositions within the context of Reward Deficiency Syndrome (RDS). Our hypothesis posits that a deficiency in gamma-type endorphins leads to persistent hyperdopaminergic activity, amplifying schizophrenia-related symptoms such as hallucinations. Thus, alcohol use may function as a physiological self-healing mechanism by increasing gamma-endorphin levels, thereby mitigating dopaminergic hyperactivity. Additionally, we propose that the DRD2 Taq1 A2 allele could offer protection against SUD in certain individuals with schizophrenia, whereas the Taq1 A1 allele may heighten susceptibility to SUD due to impaired dopaminergic reward processing. The proposed dual genetic pathways arise from the independent yet interrelated genetic bases of SUD and schizophrenia, both involving the dopamine system. Epidemiological studies reveal that psychiatric comorbidity correlates with heightened psychopathology, risky behaviors, and diminished psychosocial performance. Further advanced research, including neuroimaging, genome-wide association studies (GWAS), and epigenetic analyses, is needed to unravel the dopaminergic mechanisms underlying SUD and schizophrenia. Understanding these genetic links may pave the way for precise interventions tailored to specific subpopulations. The findings extend the conceptualization of RDS as a framework for understanding psychiatric and addictive disorders, reinforcing the critical role of dopamine dysregulation in their etiology.
In 1995, Kenneth Blum coined the term "Reward Deficiency Syndrome'(RDS) to provide the mental health field with an umbrella term expressing a dissatisfaction of everyday experiences due to a dysregulation of dopaminergic dysregulation especially the DRD2 Taq A1 polymorphism presenting with up to a 40% reduction of D2 receptors in brain tissue with two copies. While the concept of RDS as the actual real umbrella of all mental illness unlike the current DSM-V (the brain is not carved out as portrayed by this important psychiatric manual) awaits further intensive research. In fact, Steven Hyman (former director of NIMH) suggests otherwise and has urged for research related to etiological causes instead to help explain the failings of mental health. Certainly, the RDS Consortium agrees with this difficult but needed psychiatric challenge. It is noteworthy that as of 2-5-2025, there are 1615 articles listed PUBMED using the word term "Reward Deficiency" and 270 listed for RDS specifically. However, since the initial finding of the first gene discovered to associate with severe alcoholism being the DRD2A1 allele by Blum and Noble and their associates, at least 700 or more genes have been found to be involved in RDS behaviors. While this seems quite complex in a study submitted for publication elsewhere deep silico GWAS meta-meta-analysis and pharmacogenomics mining has filtered the actual gene network down to 29 as a predictive panel of RDS behaviors. However, only 15 of these genes are linked into a network and five of these genes include DRD2, DRD4, OPRMI, COMT and 5-HTTLR. Understanding the relevance of a shared genetic basis for mental illness the RDS consortium is developing novel technology to scientifically "cure" RDS via gene editing technology (e.g. Transplice molecular genetic technology). Certainly, the jury is not in as yet, but we are encouraged about the future following arduous research from the scientific community requiring "all hands on deck".
In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our "out of the box" thinking whereby we are proposing a new paradigm shift involving the " dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261 .
Personalized repetitive Transcranial Magnetic Stimulation (PrTMS®) offers an individualized approach to neuromodulation through customized treatment protocols. This case series aims to explore therapeutic outcomes of PrTMS® in two patients with post-traumatic stress disorder (PTSD), based on standardized rating scale scores and spectral EEG-guided alpha brainwave activity optimization. Participants diagnosed with PTSD received PrTMS® treatments informed by quantitative rating scales and weekly spectral EEG measurements. Weekly psychometric assessments showed an improvement in symptoms, as quantified by PCL-5 (Posttraumatic Stress Disorder Checklist for DSM-5), GAD-7 (Generalized Anxiety Disorder 7-item scale), PHQ-9 (Patient Health Questionnaire-9), and SCI (Sleep Condition Indicator) questionnaires. Specifically, PCL-5 scores demonstrated an average reduction of 20.5 points by the midpoint of treatment (4 weeks), while GAD-7 and PHQ-9 scores decreased by 7 and 8.5 points, respectively, at the end of 7 weeks. Mean SCI scores increased by 6 points by the end of the 7 week-treatment period. While previous studies have also highlighted the role of spectral EEG-directed personalized PrTMS in the treatment of PTSD, ongoing research is needed in order to understand the long-term efficacy of PrTMS®.
